medmix AG (MEDX) - Net Assets
Based on the latest financial reports, medmix AG (MEDX) has net assets worth CHF432.80 Million CHF (≈ $547.18 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF969.30 Million ≈ $1.23 Billion USD) and total liabilities (CHF536.50 Million ≈ $678.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MEDX financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF432.80 Million |
| % of Total Assets | 44.65% |
| Annual Growth Rate | 3.52% |
| 5-Year Change | -18.94% |
| 10-Year Change | N/A |
| Growth Volatility | 23.43 |
medmix AG - Net Assets Trend (2018–2025)
This chart illustrates how medmix AG's net assets have evolved over time, based on quarterly financial data. Also explore medmix AG balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for medmix AG (2018–2025)
The table below shows the annual net assets of medmix AG from 2018 to 2025. For live valuation and market cap data, see market cap of medmix AG.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF432.80 Million ≈ $547.18 Million |
-3.11% |
| 2024-12-31 | CHF446.70 Million ≈ $564.75 Million |
-5.84% |
| 2023-12-31 | CHF474.40 Million ≈ $599.77 Million |
-6.02% |
| 2022-12-31 | CHF504.80 Million ≈ $638.20 Million |
-5.45% |
| 2021-12-31 | CHF533.90 Million ≈ $674.99 Million |
+60.14% |
| 2020-12-31 | CHF333.40 Million ≈ $421.51 Million |
+12.98% |
| 2019-12-31 | CHF295.10 Million ≈ $373.09 Million |
-13.13% |
| 2018-12-31 | CHF339.70 Million ≈ $429.47 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to medmix AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 46.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CHF495.70 Million | 116.44% |
| Common Stock | CHF400.00K | 0.09% |
| Other Comprehensive Income | CHF-57.00 Million | -13.39% |
| Total Equity | CHF425.70 Million | 100.00% |
medmix AG Competitors by Market Cap
The table below lists competitors of medmix AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhubo Design
SHE:300564
|
$375.09 Million |
|
Linhai Co Ltd
SHG:600099
|
$375.15 Million |
|
Delta Plus Group SA
PA:ALDLT
|
$375.25 Million |
|
Industrial Logistics Properties Trust
NASDAQ:ILPT
|
$375.26 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
$374.97 Million |
|
Fittech Co Ltd
TW:6706
|
$374.92 Million |
|
Daeduck Co. Ltd.
KO:008060
|
$374.84 Million |
|
SGL Carbon SE
XETRA:SGL
|
$374.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in medmix AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 436,400,000 to 425,700,000, a change of -10,700,000 (-2.5%).
- Net income of 6,400,000 contributed positively to equity growth.
- Dividend payments of 15,000,000 reduced retained earnings.
- Share repurchases of 2,600,000 reduced equity.
- Other comprehensive income decreased equity by 8,600,000.
- Other factors increased equity by 9,100,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF6.40 Million | +1.5% |
| Dividends Paid | CHF15.00 Million | -3.52% |
| Share Repurchases | CHF2.60 Million | -0.61% |
| Other Comprehensive Income | CHF-8.60 Million | -2.02% |
| Other Changes | CHF9.10 Million | +2.14% |
| Total Change | CHF- | -2.45% |
Book Value vs Market Value Analysis
This analysis compares medmix AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.81x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.01x to 0.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | CHF8.23 | CHF8.32 | x |
| 2019-12-31 | CHF7.15 | CHF8.32 | x |
| 2020-12-31 | CHF8.08 | CHF8.32 | x |
| 2021-12-31 | CHF12.99 | CHF8.32 | x |
| 2022-12-31 | CHF12.28 | CHF8.32 | x |
| 2023-12-31 | CHF11.30 | CHF8.32 | x |
| 2024-12-31 | CHF10.70 | CHF8.32 | x |
| 2025-12-31 | CHF10.25 | CHF8.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently medmix AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.43%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 2.28x
- Recent ROE (1.50%) is below the historical average (4.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 15.37% | 11.50% | 0.63x | 2.11x | CHF18.23 Million |
| 2019 | 8.54% | 5.99% | 0.60x | 2.36x | CHF-4.31 Million |
| 2020 | 2.88% | 2.73% | 0.44x | 2.37x | CHF-23.74 Million |
| 2021 | 8.24% | 9.62% | 0.47x | 1.83x | CHF-9.39 Million |
| 2022 | 2.30% | 2.43% | 0.43x | 2.19x | CHF-38.88 Million |
| 2023 | 0.06% | 0.06% | 0.48x | 2.16x | CHF-46.24 Million |
| 2024 | -1.70% | -1.53% | 0.51x | 2.19x | CHF-51.04 Million |
| 2025 | 1.50% | 1.43% | 0.46x | 2.28x | CHF-36.17 Million |
Industry Comparison
This section compares medmix AG's net assets metrics with peer companies in the Specialty Industrial Machinery industry.
Industry Context
- Industry: Specialty Industrial Machinery
- Average net assets among peers: $552,435,300
- Average return on equity (ROE) among peers: 15.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| medmix AG (MEDX) | CHF432.80 Million | 15.37% | 1.24x | $375.00 Million |
| Accelleron Industries AG (ACLN) | $302.90 Million | 33.41% | 2.98x | $6.18 Billion |
| Burckhardt Compression (BCHN) | $345.03 Million | 8.01% | 1.46x | $1.91 Billion |
| Bucher Industries AG (BUCN) | $1.39 Billion | 10.81% | 0.75x | $3.61 Billion |
| Bystronic AG (BYS) | $724.20 Million | 5.05% | 0.58x | $448.35 Million |
| Feintool International Holding (FTON) | $229.93 Million | 13.94% | 1.31x | $147.25 Million |
| Georg Fischer AG (GF) | $1.37 Billion | 18.41% | 1.64x | $4.42 Billion |
| Interroll Holding AG (INRN) | $492.53 Million | 11.35% | 0.22x | $1.29 Billion |
| Kardex (KARN) | $284.90 Million | 28.33% | 0.73x | $2.02 Billion |
| Klingelnberg AG (KLIN) | $162.97 Million | 11.79% | 0.57x | $96.80 Million |
| Komax Holding AG (KOMN) | $222.10 Million | 10.46% | 0.45x | $295.64 Million |
About medmix AG
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through Healthcare; and Consumer and Industrial segments. The company offers dental products, including mixing tips and cartridges for various applications, such as prosthetics, restorations, anesthetics, and aesthetics; drug delivery devices that are used to inject fertility… Read more